1Y Target$453.89Near-term target
5Y Target$635.65Compound horizon
10Y Target$934.37Long-dated conviction
FCF$6.5bTTM · 03/26B+FCF $6.5b — strong cash profile, above most peers · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+9.3%TTM YoYBRevenue +9.3% — at or above S&P median · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.71totalBD/E 0.71 — at market average, manageable · Total D/E computed from balance sheet (short-term + long-term debt + lease obligations) ÷ stockholders equity. More accurate than native field, which often uses long-term debt only.
P/E16.3xB+P/E 16.3 — at or below S&P median, reasonable
PEG1.75proxyC+PEG 1.75 — modest premium; above fair value · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Health Care · market cap $85.7b. 3% off the 52-week high of $408.00.
Moat
ROE 12% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. $85.7b market cap gives the company enough scale to absorb fixed costs that subscale competitors can't, without yet being so large that growth has to come from acquisition.
Risk
Net margin 2.6% is thin — operating leverage cuts both ways; input-cost inflation or pricing pressure hits the bottom line first.
Horizon
1-3 yr $453.89 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $635.65 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $934.37 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.